trending Market Intelligence /marketintelligence/en/news-insights/trending/oi0gdtuaabpeqdo-clcbzq2 content esgSubNav
In This List

Pascal Biosciences plans nonbrokered private placement

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


Pascal Biosciences plans nonbrokered private placement

Pascal Biosciences Inc. plans to sell up to 12.5 million units at 40 cents apiece in a nonbrokered private placement.

The Vancouver-based biotechnology company, which makes products to treat cancer and enhance the immune system, expects gross proceeds of up to $5 million.

Each unit comprises 1 common share and 1 common share purchase warrant. Each warrant will allow the holder to buy 1 additional common share at 60 cents per share for a period of 12 months from the date of closing.

Proceeds from the offering will be used as working capital.